Critical Survey: NovelStem International (OTCMKTS:NSTM) versus Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO) and NovelStem International (OTCMKTS:NSTM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Insider & Institutional Ownership

97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.9% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 13.6% of NovelStem International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Halozyme Therapeutics and NovelStem International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1	5	6	0	2.42
NovelStem International	0	0	0	0	0.00

Halozyme Therapeutics presently has a consensus price target of $78.56, suggesting a potential upside of 15.29%. Given Halozyme Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Halozyme Therapeutics is more favorable than NovelStem International.

Profitability

This table compares Halozyme Therapeutics and NovelStem International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	22.69%	136.12%	20.69%
NovelStem International	N/A	-63.58%	2,712.21%

Risk and Volatility

Halozyme Therapeutics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, NovelStem International has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500.

Valuation & Earnings

This table compares Halozyme Therapeutics and NovelStem International”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40 billion	5.76	$316.89 million	$2.49	27.37
NovelStem International	$10,000.00	46.88	-$3.23 million	$0.06	0.17

Halozyme Therapeutics has higher revenue and earnings than NovelStem International. NovelStem International is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Halozyme Therapeutics beats NovelStem International on 10 of the 14 factors compared between the two stocks.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

About NovelStem International

NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.